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or units (normal ward = 13%, ICU = 15%, catheter laboratory or operating room = 62% 
and other = 10%). The average additional cost of any single complication was € 3,438 
(p< 0.01). Life-threatening non-access site bleeding was associated with the highest 
additional costs (€ 47,494; p< 0.05), followed by stage 3 AKI (€ 20,468; p< 0.01), implanta-
tion of a second valve (€ 16,767; p< 0.01) and other severe cardiac dysrhythmia (€ 10,611 
p< 0.05). Interestingly, censoring cases of in-hospital mortality is associated with a 
substantial decrease in the additional costs. ConClusions: Bleeding complications, 
severe kidney failure, and implantation of a second valve are the most important cost 
drivers in TAVR patients, and strategies to reduce those complications may have the 
potential to generate significant in-hospital cost reductions.
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objeCtives: There has been an increase in the number of clotting factor (CF) prod-
ucts available in the U. S. in recent years. Thrombotic events (TEs) are serious adverse 
events that can occur following administration of CFs. The objective of this study 
is to assess the same-day TE risk following exposure to CF products. Methods: 
A retrospective cohort study of individuals exposed to CF products during January 
2008 through June 2013 was conducted using HealthCore Integrated Research Database 
(HIRDSM). CF products were identified by Health care Common Procedure Coding System 
(HCPCS) codes, and TEs were ascertained via ICD-9-CM diagnosis codes. Crude same-
day TE rates (per 1,000 persons exposed) were estimated overall, by congenital clotting 
factor deficiency status and by specific CF products, age, and gender. Results: Of 3,801 
individuals exposed to CFs, 117 (30.8 per 1,000 persons) had TEs recorded on the same-
day as CF exposure. The crude same-day TE rate (per 1,000) was higher for CF users 
without congenital CF deficiency, 70.2 (102 of 1,452), as compared to those with con-
genital CF deficiency, 6.4 (15 of 2,349), unadjusted rate ratio of 11.0 (95% CI 6.4-18.9). For 
individuals without congenital CF deficiency, the crude TE rates (per 1,000) were 15.9 for 
under 15 years of age, 16.1 for 15 to 44 years, 62.8 for 45 to 64 years, and 160.9 for 65 years 
and older. The unadjusted same-day TE rates (per 1,000) ranged from 12.8 for Factor 
VIII to 204.1 for Factor IX complex product(s). Multivariable analyses are underway to 
control for potential confounders and identify recipient risk factors. ConClusions: 
The study shows an increased risk of same-day TEs for CF users without congenital 
CF deficiency and suggests a potentially substantial off-label use of CFs, which needs 
further investigation. In addition, study findings suggest elevated same-day TE rates for 
specific CF products with additional multivariable investigation ongoing.
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objeCtives: Acute myocardial infarction (AMI) is a major cause of mortality 
and disability worldwide. AMI occurs when blood flows irregularly into heart and 
thus heart muscle is injured due to insufficient constant oxygen received. It will 
cause severe complications or co-morbidities if the condition is lasting. Hence, 
we hypothesized the atrial fibrillation (AF) is an independent risk factor to the 
major severe cardiovascular events (MACE) after AMI occurred. Methods: The 
AMI patient is defined by the patient treated in the emergency room at the begin-
ning of the illness. Frequencies and costs of AMI data were extracted from the 
National Health Insurance Research Database for this observational retrospective 
cohort study between 2007 and 2012 in Taiwan. ICD-9-CM 410 was used to extract 
the AMI patients. Fisher’s exact test and categorical data analytic method were 
utilized to assess the AF as a risk factor to MACE in the AMI patients. Results: We 
mainly focused on the AMI adults without any prior MACE occurred. As a result, 
there were 3,452 AMI who can be divided into 2 groups: 2,939 AF patients and 513 
non-AF patients. The average medical cost was USD$ 3142.8 and the mean LoS 
was 10.4 days with st. d. 29.0 days. There were 1,791 MACE identified among the AF 
patients (60.9%), while there were 251 MACE among the non-AF patients (48.9%). 
In consequence, the AMI with AF resulted more MACE than those in non-AF (RR = 
1.63, C.I. = (1.35, 1.97), p < 0.0001). The difference of cost was not significant between 
both groups. The mean LoS in AF was 16.6 days, which was significantly smaller 
than that in non-AF (19.1 days). The difference was probably due to higher fatalities 
in AF. ConClusions: This study has demonstrated that AF risk is associated with 
MACE in patients after AMI occurred.
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bACkgRound: Proactive, post-authorization monitoring of drug safety and effec-
tiveness is of increasing importance. Rivaroxaban is a Factor Xa inhibitor with 
multiple indications, including: treatment of venous thromboembolism (VTE) and 
prevention of recurrent VTE; stroke prevention in atrial fibrillation; and prevention 
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objeCtives: Data are limited on the course of patients after an acute venous throm-
boembolism (VTE) event under clinical practice conditions. Methods: We present 
current data on the re-hospitalization of patients with deep venous thrombosis 
(DVT) or pulmonary embolism (PE) from the PREFER in VTE registry in 7 Western 
European countries (France, Italy, Spain, Germany, UK, Austria and Switzerland). 
The current interim analysis includes data of 2863 patients. 1689 patients had DVT 
alone and 1174 had PE (±DVT) as qualifying event for inclusion. Results: At base-
line, 72.2% of the patients received heparin, 11.9% fondaparinux, 48.0% vitamin K 
antagonists, 25.4% non-VKA oral anticoagulants, 7.0% acetylsalicylic acid, 2.1% other 
antiplatelets and 1.6% thrombolysis agents. Within the first 6 months, 14.7% of VTE 
patients were hospitalized for any reason (DVT: 12.9%, PE: 17.5%). Hospitalization 
rates varied between countries (Spain 10.7%, Germany 10.8%, France 12.5%, Italy 
19.3%, UK (at 3 months) 7.5%). The mean number of hospitalizations was 1.3 ±0.85 
(1.1 to 1.5 in the various countries; median 1, range 1-6). The documented reasons for 
hospitalization, among others, were VTE (15.3%), surgery/trauma (13.5%), bleeding 
(7.4%), or stroke/TIA (3.7%). Mean duration of all combined hospital stays was 9.8 
±12.61 days (4.0 days in Germany,  4.7 in France, 9.0 in Spain, 14.0 in Italy). The overall 
median duration of hospitalization was 6 days (interquartile range 2-12), for DVT 
cases it was 6 days (IQR 3-13), for PE cases it was 5 days (IQR 2-11). ConClusions: 
Under real-life conditions, one in seven patients had to be readmitted to hospital 
in the first 6 months after the DVT or PE event. However, the majority of hospitali-
zations were not due to the thromboembolic disease or bleeding. The duration of 
hospital stays showed a wide range across Western European countries.
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objeCtives: The great majority of patients with atrial fibrillation (AF) require life-
long antithrombotic therapy for prevention of stroke. For optimal treatment, it is 
important to investigate treatment discontinuations, as those might be associated 
with increased hospitalization rates. As potential indicator for unstable anticoagula-
tion efforts we assessed hospitalization rates for non-vitamin K antagonist oral anti-
coagulants (NOAC) and for warfarin under real-life practice conditions. Methods: 
PREFER in AF (The PREvention oF thromboembolic events – European Registry in 
Atrial Fibrillation) is a prospective non-interventional disease registry of patients 
with AF in 7 countries in Western Europe. Discontinuation rates were assessed look-
ing at all patients (n= 6412), whereas hospitalization rates reported at Baseline (BL) 
and 1 year Follow-Up (FU) focused on two groups: patients treated with warfarin 
(BL= 1379, FU= 1571) and patients treated with NOAC (BL= 194, FU= 424). Descriptive 
statistics were applied. Results: Out of 6412 patients, 9 to 18% of patients treated 
with vitamin K antagonists (VKA) discontinued therapy (warfarin 10.3%, phenpro-
coumon 9%, acenocoumarol 10.4%, fluinidone 18%). The discontinuation rates for 
patients on NOAC were 9.4% for rivaroxaban and 10.3% for dabigatran, respectively. 
Reported hospitalization rates (irrespective of reason) were 19.8%/10.0% for NOAC, 
and 24.1%/11.6% for warfarin at BL or FU, respectively. Mean duration of hospitali-
zation was 1.3±4.0/ 0.9 ±5.1 days for NOAC, and 2.0±6.1/ 1.0 ±4.2 days for warfarin.  
ConClusions: No major differences were observed in the discontinuation rates 
between VKA and NOAC on the class level nor the various available NOAC drugs. 
Hospitalization rates and corresponding number of days in hospital reported at BL 
were substantially higher compared to FU. Patients on NOAC had lower hospitaliza-
tion rates and less days in hospital compared to those on warfarin. Further analyses 
are needed to explore the reasons for hospitalizations.
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objeCtives: Transcatheter aortic valve replacement (TAVR) is a relatively new 
alternative to surgical replacement of the aortic valve. Recent development of third 
generation systems and new products have shown reductions in the frequency and 
severity of complications associated with the procedure. The aim of this study was 
to identify the cost impact of complications for patients undergoing TAVR in a German 
hospital. Methods: Data was derived from a prospective observational study, 
whereby a total of 163 consecutive patients were treated either with transfemoral 
(TF-, n= 97) or transapical (TA-) TAVR (n= 66) between February 2009 and December 
2012. Predefined clinical endpoints were analyzed, “in-hospital” costs determined 
from the hospital perspective (2012= 100) and results reported within the seven most 
relevant cost categories. Results: TF-TAVR patients experienced more minor access 
site bleeding (p= 0.017), major non-access site bleedings (p= 0.026), minor vascular 
complications (p= 0.002), stage 2 acute kidney injury (AKI, p= 0.043) and permanent 
pacemaker implantation (p< 0.001) compared with TA-TAVR. However, total in-hos-
pital costs did not differ between groups (mean € 40,348; SD € 15,851). Costs were pro-
portioned in either categories (staff = 26%, materials = 62% and infrastructure = 12%) 
